RESUMEN
Atrial fibrillation (AF) is the most common cardiac arrhythmia, and a significant risk factor for ischemic stroke and heart failure. Marketed anti-arrhythmic drugs can restore sinus rhythm, but with limited efficacy and significant toxicities, including potential to induce ventricular arrhythmia. Atrial-selective ion channel drugs are expected to restore and maintain sinus rhythm without risk of ventricular arrhythmia. One such atrial-selective channel target is GIRK1/4 (G-protein regulated inwardly rectifying potassium channel 1/4). Here we describe 14b, a potent GIRK1/4 inhibitor developed to cardiovert AF to sinus rhythm while minimizing central nervous system exposure - an issue with preceding GIRK1/4 clinical candidates.
Asunto(s)
Fibrilación Atrial , Humanos , Fibrilación Atrial/tratamiento farmacológico , Cardioversión Eléctrica , Atrios Cardíacos , EncéfaloRESUMEN
The mouse is a useful preclinical species for evaluating disease etiology due to the availability of a wide variety of genetically modified strains and the ability to perform disease-modifying manipulations. In order to establish an atrial filtration (AF) model in our laboratory, we profiled several commonly used murine AF models. We initially evaluated a pharmacological model of acute carbachol (CCh) treatment plus atrial burst pacing in C57BL/6 mice. In an effort to observe micro-reentrant circuits indicative of authentic AF, we employed optical mapping imaging in isolated mouse hearts. While CCh reduced atrial refractoriness and increased atrial tachyarrhythmia vulnerability, the left atrial (LA) excitation patterns were rather regular without reentrant circuits or wavelets. Therefore, the atrial tachyarrhythmia resembled high frequency atrial flutter, not typical AF per se. We next examined both a chronic angiotensin II (Ang II) infusion model and the surgical model of transverse aortic constriction (TAC), which have both been reported to induce atrial and ventricular structural changes that serve as a substrates for micro-reentrant AF. Although we observed some extent of atrial remodeling such as fibrosis or enlarged LA diameter, burst pacing-induced atrial tachyarrhythmia vulnerability did not differ from control mice in either model. This again suggested that an AF-like pathophysiology is difficult to demonstrate in the mouse. To continue searching for a valid murine AF model, we studied mice with a cardiac-specific deficiency (KO) in liver kinase B1 (Cardiac-LKB1), which has been reported to exhibit spontaneous AF. Indeed, the electrocardiograms (ECG) of conscious Cardiac-LKB1 KO mice exhibited no P waves and had irregular RR intervals, which are characteristics of AF. Histological evaluation of Cardiac-LKB1 KO mice revealed dilated and fibrotic atria, again consistent with AF. However, atrial electrograms and optical mapping revealed that electrical activity was limited to the sino-atrial node area with no electrical conduction into the atrial myocardium beyond. Thus, Cardiac-LKB1 KO mice have severe atrial myopathy or atrial standstill, but not AF. In summary, the atrial tachyarrhythmias we observed in the four murine models were distinct from typical human AF, which often exhibits micro- or macro-reentrant atrial circuits. Our results suggest that the four murine AF models we examined may not reflect human AF well, and raise a cautionary note for use of those murine models to study AF.
Asunto(s)
Fibrilación Atrial/fisiopatología , Modelos Animales de Enfermedad , Proteínas Quinasas Activadas por AMP/genética , Proteínas Quinasas Activadas por AMP/metabolismo , Animales , Aleteo Atrial/fisiopatología , Función del Atrio Izquierdo/fisiología , Remodelación Atrial , Carbacol/farmacología , Estimulación Cardíaca Artificial/efectos adversos , Electrocardiografía , Ratones , Ratones Endogámicos C57BL , Miocardio/patología , Miocitos Cardíacos/patología , Taquicardia Ventricular/fisiopatologíaRESUMEN
Nicotinic acid (niacin) induces beneficial changes in serum lipoproteins and has been associated with beneficial cardiovascular effects. Niacin reduces low-density lipoprotein, increases high-density lipoprotein, and decreases triglycerides. It is well established that activation of the seven-transmembrane G(i)-coupled receptor GPR109A on Langerhans cells results in release of prostaglandin D2, which mediates the well-known flushing side effect of niacin. Niacin activation of GPR109A on adipocytes also mediates the transient reduction of plasma free fatty acid (FFA) levels characteristic of niacin, which has been long hypothesized to be the mechanism underlying the changes in the serum lipid profile. We tested this "FFA hypothesis" and the hypothesis that niacin lipid efficacy is mediated via GPR109A by dosing mice lacking GPR109A with niacin and testing two novel, full GPR109A agonists, MK-1903 and SCH900271, in three human clinical trials. In mice, the absence of GPR109A had no effect on niacin's lipid efficacy despite complete abrogation of the anti-lipolytic effect. Both MK-1903 and SCH900271 lowered FFAs acutely in humans; however, neither had the expected effects on serum lipids. Chronic FFA suppression was not sustainable via GPR109A agonism with niacin, MK-1903, or SCH900271. We conclude that the GPR109A receptor does not mediate niacin's lipid efficacy, challenging the long-standing FFA hypothesis.
Asunto(s)
Ácidos Grasos/metabolismo , Niacina/farmacología , Receptores Acoplados a Proteínas G/metabolismo , Receptores Nicotínicos/metabolismo , Animales , Relación Dosis-Respuesta a Droga , Ácidos Grasos/sangre , Humanos , Lipólisis/efectos de los fármacos , Lipoproteínas/sangre , Masculino , Ratones , Ratones Endogámicos C57BL , Niacina/administración & dosificación , Pirazoles/farmacología , Receptores Acoplados a Proteínas G/agonistasRESUMEN
G-protein coupled receptor (GPCR) GPR109a is a molecular target for nicotinic acid and is expressed in adipocytes, spleen, and immune cells. Nicotinic acid has long been used for the treatment of dyslipidemia due to its capacity to positively affect serum lipids to a greater extent than other currently marketed drugs. We report a series of tricyclic pyrazole carboxylic acids that are potent and selective agonists of GPR109a. Compound R,R-19a (MK-1903) was advanced through preclinical studies, was well tolerated, and presented no apparent safety concerns. Compound R,R-19a was advanced into a phase 1 clinical trial and produced a robust decrease in plasma free fatty acids. On the basis of these results, R,R-19a was evaluated in a phase 2 study in humans. Because R,R-19a produced only a weak effect on serum lipids as compared with niacin, we conclude that the beneficial effects of niacin are most likely the result of an undefined GPR109a independent pathway.
Asunto(s)
Ácidos Grasos no Esterificados/sangre , Pirazoles/uso terapéutico , Receptores Acoplados a Proteínas G/agonistas , Animales , Humanos , Hipolipemiantes/farmacocinética , Hipolipemiantes/uso terapéutico , Masculino , Niacina/farmacología , Pirazoles/síntesis química , Pirazoles/farmacocinética , Ratas , Receptores Acoplados a Proteínas G/efectos de los fármacos , Receptores Nicotínicos/efectos de los fármacos , Estereoisomerismo , Vasodilatadores/farmacologíaRESUMEN
Amino-anthranilic acid derivatives have been identified as a new class of low serum shifted, high affinity full agonists of the human orphan G-protein-coupled receptor GPR109a with improved ADME properties.
Asunto(s)
Descubrimiento de Drogas , Receptores Acoplados a Proteínas G/agonistas , Animales , Flúor/química , Humanos , Concentración 50 Inhibidora , Ratones , Estructura Molecular , Niacina/síntesis química , Niacina/química , Niacina/farmacología , Piridinas/síntesis química , Piridinas/química , Ratas , Ratas Sprague-Dawley , Receptores NicotínicosRESUMEN
5-Alkyl and aryl-pyrazole-acids have been identified as a new class of selective, small-molecule, agonists of the human orphan G-protein-coupled receptor GPR109a, a high affinity receptor for the HDL-raising drug nicotinic acid.
Asunto(s)
Pirazoles/química , Receptores Acoplados a Proteínas G/agonistas , Animales , Ácidos Grasos/metabolismo , Humanos , Ratones , Niacina/química , Pirazoles/síntesis química , Pirazoles/farmacocinética , Receptores Acoplados a Proteínas G/metabolismo , Receptores Nicotínicos/metabolismoRESUMEN
A series of pyrazolyl propionyl cyclohexenamides were discovered as full agonists for the high affinity niacin receptor GPR109A. The structure-activity relationship (SAR) studies were aimed to improve activity on GPR109A, reduce Cytochrome P450 2C8 (CYP2C8) and Cytochrome P450 2C9 (CYP2C9) inhibition, reduce serum shift and improve pharmacokinetic (PK) profiles.
Asunto(s)
Amidas/química , Ciclohexenos/farmacología , Receptores Acoplados a Proteínas G/agonistas , Animales , Ciclohexenos/química , Ciclohexenos/farmacocinética , Ratones , Ratas , Receptores Nicotínicos , Relación Estructura-ActividadRESUMEN
OBJECTIVE: To examine the effects of treatments with niacin or anacetrapib (an inhibitor of cholesteryl ester transfer protein) on the ability of high-density lipoprotein (HDL) to promote net cholesterol efflux and reduce toll-like receptor-mediated inflammation in macrophages. METHODS AND RESULTS: A total of 18 patients received niacin, 2 g/d, for 4 weeks; 20 patients received anacetrapib, 300 mg/d, for 8 weeks; and 2 groups (n=4 and n=5 patients) received placebo. HDL samples were isolated by polyethylene glycol precipitation or ultracentrifugation, tested for the ability to promote cholesterol efflux in cholesterol-loaded THP-I or mouse peritoneal macrophages, or used to pretreat macrophages, followed by lipopolysaccharide exposure. HDL cholesterol levels were increased by 30% in response to niacin and by approximately 100% in response to anacetrapib. Niacin treatment increased HDL-mediated net cholesterol efflux from foam cells, primarily by increasing HDL concentration, whereas anacetrapib treatment increased cholesterol efflux by both increasing HDL concentration and causing increased efflux at matched HDL concentrations. The increased efflux potential of anacetrapib-HDL was more prominent at higher HDL cholesterol concentrations (>12 microg/mL), which was associated with an increased content of lecithin-cholesterol acyltransferase (LCAT) and apolipoprotein E and completely dependent on the expression of ATP binding cassette transporters (ABCA1 and ABCG1). Potent antiinflammatory effects of HDL were observed at low HDL concentrations (3 to 20 microg/mL) and were partly dependent on the expression of ABCA1 and ABCG1. All HDL preparations showed similar antiinflammatory effects, proportionate to the HDL cholesterol concentration. CONCLUSIONS: Niacin treatment caused a moderate increase in the ability of HDL to promote net cholesterol efflux, whereas inhibition of cholesteryl ester transfer protein via anacetrapib led to a more dramatic increase in association with enhanced particle functionality at higher HDL concentrations. All HDLs exhibited potent ability to suppress macrophage toll-like receptor 4-mediated inflammatory responses, in a process partly dependent on cholesterol efflux via ABCA1 and ABCG1.
Asunto(s)
Antiinflamatorios/uso terapéutico , Proteínas de Transferencia de Ésteres de Colesterol/antagonistas & inhibidores , HDL-Colesterol/sangre , Colesterol/sangre , Dislipidemias/tratamiento farmacológico , Hipolipemiantes/uso terapéutico , Inflamación/prevención & control , Macrófagos/metabolismo , Niacina/uso terapéutico , Oxazolidinonas/uso terapéutico , Transportador 1 de Casete de Unión a ATP , Transportador de Casetes de Unión a ATP, Subfamilia G, Miembro 1 , Transportadoras de Casetes de Unión a ATP/genética , Transportadoras de Casetes de Unión a ATP/metabolismo , Animales , Antiinflamatorios/efectos adversos , Células Cultivadas , Proteínas de Transferencia de Ésteres de Colesterol/metabolismo , Ensayos Clínicos como Asunto , Dislipidemias/sangre , Dislipidemias/inmunología , Células Espumosas/metabolismo , Humanos , Hipolipemiantes/efectos adversos , Inflamación/inmunología , Inflamación/metabolismo , Mediadores de Inflamación/metabolismo , Lipoproteínas/deficiencia , Lipoproteínas/genética , Lipoproteínas/metabolismo , Macrófagos/inmunología , Ratones , Ratones Noqueados , Niacina/efectos adversos , Oxazolidinonas/efectos adversos , Factores de Tiempo , Receptor Toll-Like 4/metabolismo , Resultado del TratamientoRESUMEN
Tricyclic pyrazole tetrazoles which are potent partial agonists of the high affinity niacin receptor, GPR109a, have been discovered and optimized. One of these compounds has proven to be effective at lowering free fatty acids in vitro and in vivo.
Asunto(s)
Pirazoles/química , Receptores Acoplados a Proteínas G/agonistas , Tetrazoles/química , Vasodilatadores/química , Animales , Perros , Haplorrinos , Humanos , Ratones , Ratas , Receptores Acoplados a Proteínas G/metabolismo , Receptores Nicotínicos/metabolismo , Tetrazoles/síntesis química , Tetrazoles/farmacocinética , Vasodilatadores/síntesis química , Vasodilatadores/farmacocinéticaRESUMEN
Biaryl cyclohexene carboxylic acids were discovered as full and potent niacin receptor (GPR109A) agonists. Compound 1e (MK-6892) displayed excellent receptor activity, good PK across species, remarkably clean off-target profiles, good ancillary pharmacology, and superior therapeutic window over niacin regarding the FFA reduction versus vasodilation in rats and dogs.
Asunto(s)
Ácidos Carboxílicos/farmacología , Ácidos Ciclohexanocarboxílicos/farmacología , Ciclohexenos/química , Descubrimiento de Drogas , Oxadiazoles/farmacología , Receptores Acoplados a Proteínas G/agonistas , Animales , Área Bajo la Curva , Unión Competitiva , Células CHO , Ácidos Carboxílicos/química , Ácidos Carboxílicos/farmacocinética , Cricetinae , Cricetulus , Ácidos Ciclohexanocarboxílicos/química , Ácidos Ciclohexanocarboxílicos/farmacocinética , Perros , Evaluación Preclínica de Medicamentos , Ácidos Grasos no Esterificados/sangre , Humanos , Tasa de Depuración Metabólica , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Modelos Químicos , Estructura Molecular , Oxadiazoles/química , Oxadiazoles/farmacocinética , Ratas , Receptores Acoplados a Proteínas G/genética , Receptores Acoplados a Proteínas G/metabolismo , Receptores Nicotínicos/genética , Receptores Nicotínicos/metabolismo , Relación Estructura-Actividad , Vasodilatación/efectos de los fármacosRESUMEN
5-Alkyl and aryl-pyrazole-tetrazoles have been identified as a new class of selective, small-molecule, agonists of the human G-protein-coupled receptor GPR109a, a high affinity receptor for the HDL-raising drug nicotinic acid.
Asunto(s)
Pirazoles/química , Receptores Acoplados a Proteínas G/agonistas , Tetrazoles/química , Animales , Humanos , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Agonistas Nicotínicos/química , Agonistas Nicotínicos/farmacología , Pirazoles/farmacología , Receptores Acoplados a Proteínas G/deficiencia , Receptores Acoplados a Proteínas G/fisiología , Receptores Nicotínicos/deficiencia , Receptores Nicotínicos/fisiología , Tetrazoles/farmacología , Vasodilatación/efectos de los fármacos , Vasodilatación/fisiologíaRESUMEN
Tricyclic analogues were rationally designed as the high affinity niacin receptor G-protein-coupled receptor 109A (GPR109A) agonists by overlapping three lead structures. Various tricyclic anthranilide and cycloalkene carboxylic acid full agonists were discovered with excellent in vitro activity. Compound 2g displayed a good therapeutic index regarding free fatty acids (FFA) reduction and vasodilation effects in rats, with very weak cytochrome P450 2C8 (CYP2C8) and cytochrome P450 2C9 (CYP2C9) inhibition, and a good mouse pharmacokinetics (PK) profile.
Asunto(s)
Cicloparafinas/síntesis química , Rubor/inducido químicamente , Compuestos Heterocíclicos con 3 Anillos/síntesis química , Hipolipemiantes/síntesis química , Niacina/metabolismo , Receptores Acoplados a Proteínas G/agonistas , ortoaminobenzoatos/síntesis química , Adipocitos/efectos de los fármacos , Adipocitos/metabolismo , Animales , Células CHO , Cricetinae , Cricetulus , Cicloparafinas/efectos adversos , Cicloparafinas/farmacología , Oído/irrigación sanguínea , Compuestos Heterocíclicos con 3 Anillos/efectos adversos , Compuestos Heterocíclicos con 3 Anillos/farmacología , Humanos , Hipolipemiantes/efectos adversos , Hipolipemiantes/farmacología , Técnicas In Vitro , Lipólisis , Masculino , Ratones , Ensayo de Unión Radioligante , Ratas , Receptores Nicotínicos , Relación Estructura-Actividad , Vasodilatación/efectos de los fármacos , ortoaminobenzoatos/efectos adversos , ortoaminobenzoatos/farmacologíaRESUMEN
Phenolic acids are found in abundance throughout the plant kingdom. Consumption of wine or other rich sources of phenolic acids, such as the "Mediterranean diet," has been associated with a lower risk of cardiovascular disease. The underlying mechanism(s), however, has remained unclear. Here, we show that many phenolic acids, including those from the hydroxybenzoic and hydroxycinnamic acid classes, can bind and activate GPR109A (HM74a/PUMA-G), the receptor for the antidyslipidemic agent nicotinic acid. In keeping with this activity, treatment with a number of phenolic acids, including cinnamic acid, reduces lipolysis in cultured human adipocytes and in fat pats isolated from wild-type mice but not from mice deficient of GPR109A. Oral administration of cinnamic acid significantly reduces plasma levels of FFA in the wild type but not in mice deficient of GPR109A. Activation of GPR109A by phenolic acids may thus contribute to a cardiovascular benefit of these plant-derived products.
Asunto(s)
Adipocitos/metabolismo , Hidroxibenzoatos/metabolismo , Lipólisis/fisiología , Receptores Acoplados a Proteínas G/metabolismo , Receptores Nicotínicos/metabolismo , Adipocitos/citología , Adipocitos/efectos de los fármacos , Animales , Células Cultivadas , Cinamatos/química , Cinamatos/metabolismo , Cinamatos/farmacología , Guanosina 5'-O-(3-Tiotrifosfato)/metabolismo , Humanos , Hidroxibenzoatos/química , Hidroxibenzoatos/farmacología , Masculino , Ratones , Ratones Noqueados , Estructura Molecular , Extractos Vegetales/química , Extractos Vegetales/metabolismo , Ensayo de Unión Radioligante , Receptores Acoplados a Proteínas G/genética , Receptores Nicotínicos/genéticaRESUMEN
Heavy exercise or oxygen deficit often links with higher levels of arterial lactate and lower levels of plasma free fatty acids (FFA). Treatment with lactate reduces circulating levels of FFA in vivo and lipolysis in adipose tissues in vitro. However, the underlying mechanism has remained unclear. Here we employ pharmacological and genetic approaches to show that GPR81, an orphan G-protein-coupled receptor with relatively restricted expression in the adipose tissues, functions as a receptor for lactate and can mediate an anti-lipolytic effect of lactate. GPR81 may thus function as a sensor of lactate that can modulate the FFA pool under exercise or conditions of oxygen deficit.
Asunto(s)
Tejido Adiposo/metabolismo , Ácidos Grasos no Esterificados/metabolismo , Ácido Láctico/metabolismo , Lipólisis , Receptores Acoplados a Proteínas G/fisiología , Tejido Adiposo/efectos de los fármacos , Animales , Células CHO , Cricetinae , Cricetulus , Humanos , Ácido Láctico/farmacología , Ligandos , Lipólisis/efectos de los fármacos , Lipólisis/genética , Ratones , Receptores Acoplados a Proteínas G/agonistas , Receptores Acoplados a Proteínas G/genética , Receptores Nicotínicos/genética , Receptores Nicotínicos/fisiología , TransfecciónRESUMEN
A homology model of the nicotinic acid receptor GPR109A was constructed based on the X-ray crystal structure of bovine rhodopsin. An HTS hit was docked into the homology model. Characterization of the binding pocket by a grid-based surface calculation of the docking model suggested that a larger hydrophobic body plus a polar tail would improve interaction between the ligand and the receptor. The designed compounds were synthesized, and showed significantly improved binding affinity and activation of GPR109A.
Asunto(s)
Modelos Moleculares , Agonistas Nicotínicos/síntesis química , Agonistas Nicotínicos/farmacología , Receptores Acoplados a Proteínas G/agonistas , ortoaminobenzoatos/síntesis química , ortoaminobenzoatos/farmacología , Sitios de Unión , Técnicas Químicas Combinatorias , Humanos , Estructura Molecular , Niacina/metabolismo , Agonistas Nicotínicos/química , Receptores Nicotínicos , Relación Estructura-Actividad , ortoaminobenzoatos/químicaRESUMEN
Pyrazolopyrimidines were discovered as the first class of allosteric agonists for the high affinity nicotinic acid receptor GPR109A. In addition to its intrinsic activity, compound 9n significantly enhances nicotinic acid binding to the receptor, thereby potentiating the functional efficacy of nicotinic acid.
Asunto(s)
Agonistas Nicotínicos/síntesis química , Agonistas Nicotínicos/farmacología , Pirazoles/síntesis química , Pirazoles/farmacología , Pirimidinas/síntesis química , Pirimidinas/farmacología , Receptores Acoplados a Proteínas G/agonistas , Sitios de Unión , Técnicas Químicas Combinatorias , Humanos , Estructura Molecular , Niacina/metabolismo , Agonistas Nicotínicos/química , Pirazoles/química , Pirimidinas/química , Receptores Nicotínicos , Relación Estructura-ActividadRESUMEN
The discovery and profiling of 3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (5a, MK-0354), a partial agonist of GPR109a, is described. Compound 5a retained the plasma free fatty acid lowering effects in mice associated with GPR109a agonism, but did not induce vasodilation at the maximum feasible dose. Moreover, preadministration of 5a blocked the flushing effect induced by nicotinic acid but not that induced by PGD2. This profile made 5a a suitable candidate for further study for the treatment of dyslipidemia.
Asunto(s)
Hipolipemiantes/farmacología , Pirazoles/farmacocinética , Receptores Acoplados a Proteínas G/agonistas , Tetrazoles/farmacocinética , Adipocitos/efectos de los fármacos , Animales , Ácidos Grasos no Esterificados/sangre , Humanos , Hipolipemiantes/síntesis química , Hipolipemiantes/uso terapéutico , Lipólisis/efectos de los fármacos , Masculino , Ratones , Ratones Endogámicos C57BL , Pirazoles/síntesis química , Receptores Nicotínicos , Tetrazoles/síntesis química , Vasodilatación/efectos de los fármacosRESUMEN
The design, synthesis, and biological activity of a series of cycloalkene acid-based niacin receptor agonists are described. This led to the discovery that tetrahydro anthranilic acid is an excellent surrogate for anthranilic acid. Several compounds were identified that were potent against the niacin receptor, had enhanced cytochrome P450 selectivity against subtypes CYP2C8 and CYP2C9, and improved oral exposure in mice.
Asunto(s)
Ciclohexenos/síntesis química , Ciclohexenos/farmacología , Ciclopentanos/síntesis química , Ciclopentanos/farmacología , Sistema Enzimático del Citocromo P-450/metabolismo , Agonistas Nicotínicos/síntesis química , Agonistas Nicotínicos/farmacología , ortoaminobenzoatos/síntesis química , ortoaminobenzoatos/farmacología , Animales , Hidrocarburo de Aril Hidroxilasas/efectos de los fármacos , Ciclohexenos/química , Ciclohexenos/farmacocinética , Ciclopentanos/química , Ciclopentanos/farmacocinética , Citocromo P-450 CYP2C8 , Citocromo P-450 CYP2C9 , Diseño de Fármacos , Humanos , Ratones , Agonistas Nicotínicos/química , Antagonistas Nicotínicos/farmacología , ortoaminobenzoatos/química , ortoaminobenzoatos/farmacocinéticaRESUMEN
Biaryl anthranilides are reported as potent and selective full agonists for the high affinity niacin receptor GPR109A. The SAR presented outlines approaches to reduce serum shift and both CYPCYP2C8 and CYP2C9 liabilities, while improving PK and maintaining excellent receptor activity. Compound 2i exhibited good in vivo antilipolytic efficacy while providing a significantly improved therapeutic index over vasodilation (flushing) with respect to niacin in the mouse model.
Asunto(s)
Receptores Acoplados a Proteínas G/agonistas , ortoaminobenzoatos/síntesis química , Amidas/síntesis química , Amidas/farmacocinética , Amidas/farmacología , Animales , Hidrocarburo de Aril Hidroxilasas/antagonistas & inhibidores , Unión Competitiva , Células CHO , Cricetinae , Cricetulus , Citocromo P-450 CYP2C8 , Citocromo P-450 CYP2C9 , Humanos , Técnicas In Vitro , Ratones , Microsomas Hepáticos/metabolismo , Ensayo de Unión Radioligante , Receptores Nicotínicos , Relación Estructura-Actividad , ortoaminobenzoatos/farmacocinética , ortoaminobenzoatos/farmacologíaRESUMEN
A urea class of high affinity niacin receptor agonists was discovered. Compound 1a displayed good PK, better in vivo efficacy in reducing FFA in mouse than niacin, and no vasodilation in a mouse model. Compound 1q demonstrated equal affinity to GPR109A as niacin.